CytoVale, a San Francisco, CA-based developer of a new class of biomarkers based on the mechanical properties of individual cells, or mechanomics, received an investment of undisclosed amount.
Breakout Labs, the program of the Thiel Foundation, which invests in early-stage science and technology companies, provided the funding.
Led by CEO Ajay Shah, Ph.D., and co-founder Dino Di Carlo, Ph.D. (UCLA Professor), CytoVale uses microfluidics to route and physically probe individual cells. It can measure over 10 biophysical cell markers at rates above 2,000 cells per second, providing a high-throughput, low-cost method of detecting disease.
The company had already received a $200k SBIR Award (read here).